Beverly Hills Private Wealth LLC acquired a new position in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) in the second quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 22,156 shares of the medical instruments supplier's stock, valued at approximately $3,353,000.
Other institutional investors also recently added to or reduced their stakes in the company. OneDigital Investment Advisors LLC purchased a new position in shares of Becton, Dickinson and Company in the 2nd quarter worth approximately $1,282,000. Plato Investment Management Ltd purchased a new stake in shares of Becton, Dickinson and Company during the 2nd quarter valued at $1,728,000. Bell Investment Advisors Inc acquired a new stake in shares of Becton, Dickinson and Company in the 2nd quarter worth $29,000. AMG National Trust Bank acquired a new stake in shares of Becton, Dickinson and Company in the 2nd quarter worth $398,000. Finally, Avise Financial Cooperative Inc. acquired a new position in Becton, Dickinson and Company during the 2nd quarter valued at about $236,000. Institutional investors own 86.97% of the company's stock.
Analyst Ratings Changes
Several equities analysts have recently issued reports on the stock. Stifel Nicolaus set a $195.00 price objective on shares of Becton, Dickinson and Company in a report on Friday, August 7th. Royal Bank Of Canada boosted their target price on shares of Becton, Dickinson and Company from $180.00 to $190.00 and gave the stock a "sector perform" rating in a research report on Thursday. Citigroup restated a "buy" rating on shares of Becton, Dickinson and Company in a research note on Thursday. TD Cowen raised their price target on shares of Becton, Dickinson and Company from $163.00 to $182.00 and gave the stock a "hold" rating in a report on Wednesday, August 5th. Finally, Bank of America lowered their price objective on shares of Becton, Dickinson and Company from $177.00 to $170.00 in a research note on Friday, June 12th. Eight research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of "Hold" and an average price target of $185.67.
Read Our Latest Research Report on Becton, Dickinson and Company
Becton, Dickinson and Company Stock Down 0.1%
Becton, Dickinson and Company stock opened at $183.16 on Monday. The business's 50-day moving average price is $157.84 and its 200 day moving average price is $161.41. The company has a quick ratio of 0.51, a current ratio of 0.87 and a debt-to-equity ratio of 0.55. The firm has a market cap of $50.47 billion, a price-to-earnings ratio of 55.17, a price-to-earnings-growth ratio of 12.93 and a beta of 0.19. Becton, Dickinson and Company has a 52 week low of $127.59 and a 52 week high of $187.35.
Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share for the quarter, topping analysts' consensus estimates of $3.14 by $0.09. The company had revenue of $4.98 billion during the quarter, compared to analysts' expectations of $4.89 billion. Becton, Dickinson and Company had a return on equity of 14.79% and a net margin of 4.52%.Becton, Dickinson and Company's quarterly revenue was up 5.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $3.68 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. As a group, sell-side analysts anticipate that Becton, Dickinson and Company will post 12.67 earnings per share for the current year.
Becton, Dickinson and Company Announces Dividend
The business also recently announced a quarterly dividend, which will be paid on Wednesday, September 30th. Shareholders of record on Wednesday, September 9th will be paid a $1.05 dividend. The ex-dividend date of this dividend is Wednesday, September 9th. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.3%. Becton, Dickinson and Company's dividend payout ratio (DPR) is 126.51%.
Insider Transactions at Becton, Dickinson and Company
In related news, EVP Roland Goette sold 2,438 shares of the firm's stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $180.84, for a total transaction of $440,887.92. Following the completion of the sale, the executive vice president directly owned 14,856 shares in the company, valued at approximately $2,686,559.04. This trade represents a 14.10% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Thomas E. Polen, Jr. sold 4,152 shares of Becton, Dickinson and Company stock in a transaction dated Thursday, August 13th. The stock was sold at an average price of $185.00, for a total transaction of $768,120.00. Following the transaction, the chief executive officer directly owned 110,163 shares in the company, valued at $20,380,155. This trade represents a 3.63% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 11,779 shares of company stock worth $1,974,669 in the last quarter. Company insiders own 0.40% of the company's stock.
Becton, Dickinson and Company Profile
(
Free Report)
Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD's products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company's operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.
BD's product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Becton, Dickinson and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Becton, Dickinson and Company wasn't on the list.
While Becton, Dickinson and Company currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
